Axsome Therapeutics Inc.

AXSM | NASDAQ

Price Alert Chart Builder DCF Calculator

$204.92

-$2.86 (-1.38%)

Sep 21, 2026, 1:53 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-1.38%

(1D)

Rating

Updated: Aug 27, 2026

31.1

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $10.55B

1D Range

203.17 210.85

52W Range

114.91 260.19

Valuation (TTM)

PE -55.41

PB 128.35

EV/EBITDA -58.91

Valuation (NTM)

Forward PE 38.31

Forward PEG 0.20

Price Target $282.53

Cash Flow

FCF Yield -0.7%

SBC Adj. FCF Yield -1.6%

SBC Impact -135.1%

Margins

Gross Margin 93.2%

Operating Margin -24.3%

FCF Margin -9.2%

Growth (CAGR)

Revenue 3Y | 5Y 62.0% | 52.7%

Dil EPS 3Y | 5Y 27.0% | -1.0%

FCF 3Y | 5Y 40.2% | 7.8%

Returns

ROA -25.2%

ROE -255.6%

ROIC -50.7%

Financial Health

Net Cash

$131.89M

Current Ratio 1.43

Interest Coverage -37.58

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. It...

Sector Healthcare

Industry Biotechnology

Employees 1,346

IPO Date Nov 18, 2015

Website www.axsome.com

Fiscal Year January - December

Full Company Profile

Latest News

10 hours ago · globenewswire.com

Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer's Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer's Day

The Shared Goals: Navigating Alzheimer's Agitation survey finds that Alzheimer's disease agitation is often only recognized after daily life is significantly disrupted Ninety-seven percent of care partners reported that agitation negatively impacted their loved one's quality of life, and three in four wish they had recognized symptoms sooner Results from the survey were recently presented at Psych Congress 2026 in New Orleans, Louisiana Survey conducted by The Harris Poll and in collaboration with CaringKind NEW YORK, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today, in connection with World Alzheimer's Day, announced results of the Shared Goals: Navigating Alzheimer's Agitation survey that highlight the profound impact that symptoms of agitation can have on people with Alzheimer's disease and their family care partners.

15 hours ago · defenseworld.net

Axsome Sees AUVELITY Prescriptions Accelerate as Alzheimer’s Launch Gains Traction

Axsome Therapeutics (NASDAQ: AXSM) executives said the company is seeing accelerating prescription growth for AUVELITY following its sales-force expansion and the recent launch of the drug in Alzheimer's disease agitation, while management expects operating expenses to remain relatively stable in the second half of the year. Speaking at Morgan Stanley's Global Healthcare Conference, Chief Financial Officer

2 days ago · marketbeat.com

Axsome Sees AUVELITY Prescriptions Accelerate as Alzheimer's Launch Gains Traction

Axsome Therapeutics NASDAQ: AXSM executives said the company is seeing accelerating prescription growth for AUVELITY following its sales-force expansion and the recent launch of the drug in Alzheimer's disease agitation, while management expects operating expenses to remain relatively stable in the second half of the year.

2 days ago · marketbeat.com

Axsome Therapeutics Highlights Auvelity Growth, Pipeline Progress at H.C. Wainwright Conference

Axsome Therapeutics NASDAQ: AXSM executives highlighted growth across its commercial portfolio, an expanded sales force and multiple late-stage clinical programs during the H.C. Wainwright 28th Annual Global Investment Conference.

2 days ago · fool.com

Analysts Think Axsome Therapeutics Stock Could Soar 35% Over the Next 12 Months. Is the Stock a No-Brainer Buy?

Axsome Therapeutics' revenue is growing at a good clip. The company has a deep pipeline as well.

3 days ago · fool.com

Axsome Therapeutics vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?

Axsome Therapeutics is generating rapid revenue growth through its expanding portfolio of commercialized central nervous system treatments. Revolution Medicines is advancing a high-potential pipeline of RAS(ON) inhibitors aimed at treating some of the most difficult cancers.

3 days ago · fool.com

Is Axsome Therapeutics a Buy on the Dip?

Axsome Therapeutics has launched exciting new drugs over the past year, and they are delivering growth. The biopharma player's late-stage pipeline could translate into additional products over the next few years.

4 days ago · globenewswire.com

Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026

NEW YORK, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced presentations of new data in major depressive disorder and Alzheimer's disease agitation and eight additional encore data posters spanning its psychiatry and neurology portfolio at Psych Congress 2026, being held September 15-19, in New Orleans, Louisiana.